Disclosures noted below. The AAP has taken steps to resolve any potential conflicts of interest. None of the editors, board members, reviewers, question writers, PREP Coordinating the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial off-label pharmaceutical use, investigational therapies, brand names, and manufacturers. Each of the editorial board members, reviewers, question writers, PREP Coordinating relationships and resolution of conflicts of interest for AAP CME activities is The American Academy of Pediatrics (AAP) Policy on Disclosure of Financial Relationships and Resolution of Conflicts of Interest for AAP CME Activities is American Academy of Pediatrics Customer Service Center, 141 Northwest Point Blvd., Elk Grove Village, IL 60007-1098. Statements and opinions expressed in this publication do not necessarily reflect the views of the American Academy of Pediatrics or its subsections. Articles are available to Fellows and Candidate Members of the AAP. The AAP designates this journal-based CME activity for a maximum of 1.00 Category 1 Credits™ (AMA PRA CME Program®) to provide continuing medical education for physicians. CME statements:

1. Meaghann Weaver, Clifford Mauriello
3. Gabrielle Geddes, Mark M. Butterly, Sonali Mehta Patel, Gary L. Rogers, Catherine Olson Jordan
4. Silvio Marra
5. Athos Bousvaros, MD, MPH, FAAP, disclosed that he has research grants from Merck and product knowledge translation role at EMD Serono, a division of Merck KGaA, Darmstadt, Germany. Richard Sills, MD, FAAP, disclosed that he receives a research grant from Novartis. Miriam Weinstein, MD, disclosed that she is a consultant for Pediapharm.